Slide 1: FY24 Results and Capital Raising
FY24 Results and Capital Raising 3 April 2025
Slide 2: Agenda
Agenda FY24 Results and Capital Raising 1. Overview 2. Results Highlights 3. Financials 4. Strategy & Outlook 5. Capital Raising 2
Slide 3: Overview
imexHSs Overview
Slide 4: Investment Highlights
Investment Highlights • FY24 results highlights: ➢ FY24 revenue of $26.5m, up 34% vs pcp; up 27% on a constant currency basis ➢ FY24 Underlying EBITDA was a profit of $0.5m; $0.2m in pcp ➢ ARR of $30.0m, up 20% vs pcp; up 24% on a constant currency basis ➢ Cash of $2.1m at 31 Dec 2024, down from $2.
Slide 5: One Company with two businesses democratising access to medical imaging expertise
One Company with two businesses aimed at democratising access to medical imaging expertise Medical Imaging Software Radiology Services Provider of innovative, cloud-based, Outsourcing of imaging facilities AI medical imaging software and teleradiology to hospitals and solutions medical facilities 5
Slide 6: Global footprint
Global footprint Software 18 countries; 518 sites 3,326 radiologists 27 distributors in 16 countries Radiology Colombia, Spain and Mexico 36 radiology centres 160+ in-house radiologists 6
Slide 7: FY24 Results Highlights
imexHs FY24 Results Highlights
Slide 8: Business Highlights
Business Highlights • The Company is focused on generating positive earnings and cashflow. • Geographic attention remains within Latin America. • Sales on plan and pipeline for both IMEXHS Cloud and Enterprise radiology solutions remains robust. • New Value Proposition major software development rem
Slide 9: FY24 Operational Highlights
FY24 Operational Highlights • Enterprise software contract renewal with • Good progress has been made with existing Colsubsidio with improved terms and pricing. software clients in extending both the scope of The 3-year software contract is expected to services and additional sites. contribute $575,
Slide 10: FY24 Operational Highlights
FY24 Operational Highlights • New radiology services contract signed with an existing customer in Colombia with expected ARR of $564,000 with improved margins. • Fourth consecutive Colombian National Police contract renewal including price and terms increases contributing new ARR of $352,000, taking
Slide 11: FY24 Financial Highlights
FY24 Financial Highlights Sales Revenue Annual Recurring Underlying Revenue (ARR) 2 EBITDA3 Up 34% yoy $26.5m Up 20% yoy $30.0m vs $0.2m4 in pcp Up 27% on a constant Up 24% on a constant currency basis1 currency basis $0.5m Recurring Closing cash Debt revenue 97% of total revenue $25.8m vs $2.4m at
Slide 12: FY24 Business Unit Results
FY24 Business Unit Results $M Software Radiology Corporate Total Revenue 8.9 17.6 - 26.5 Underlying 3.1 0.1 (2.7) 0.5 EBITDA ARR 9.9 20.1 - 30.0 • Software primarily relates to sales of IMEXHS Enterprise and growing IMEXHS Cloud business ➢ Revenue up 17% vs pcp ➢ ARR up 9% vs pcp ➢ Underlying EBITDA
Slide 13: Progress in ARR
Progress in ARR ARR as at 31 December 2024 • $30.0m, up 20% vs 31 Dec-23: ➢ Software - $9.9m, up 9% vs $9.1m at 31 Dec-23; and ➢ Radiology services - $20.1m, up 26% vs $15.9m at 31 Dec-23. (1) Constant currency basis assumes that historical results at each year end are converted at the 31 Dec-24 exc
Slide 14: FY24 Financials
ime>«Hs FY24 Financials
Slide 15: Income Statement
Income Statement #039;000 FY24 FY23 Var Var % • Revenue of $26.5m, up 34% yoy and Revenue 26,450 19,669 6,781 34% 27% on a constant currency basis Other revenue 120 252 (132) (52%) • Underlying EBITDA of $0.5m up Total revenue 26,569 19,921 6,648 33% $0.3m versus pcp profit of $0.2m • One-off goodwill
Slide 16: Balance Sheet
Balance Sheet #039;000 Dec-24 Dec 23 • Closing cash balance of $2.1m at 31 Dec-24 and Cash 2,072 2,362 Net Assets of $14.5m. Trade & other receivables 6,856 6,443 • Intangible assets of $8.1m include Goodwill of Inventories 328 112 $4.6m, Software of $2.6m, $0.8m of customer Current assets 9,256 8,917
Slide 17: Summary Cash Flow
Summary Cash Flow #039;000 FY24 FY23 • Closing cash balance of $2.1m as at 31-Dec-24 vs pcp of $2.4m. Net cash (used in)/from operating activities (635) 2,610 • Revenue growth in the year consumed Net cash (used in)/from investing activities (766) (2,133) significant working capital leading to Net cash
Slide 18: Strategy & Outlook
imexHs Strategy & Outlook
Slide 19: New Value Proposition
New Value Proposition Radiologists with Superpowers 1 Product. “An advanced, contemporary and secure radiology AI enhanced software solution.” - New multitenant cloud-native RIS developed. - Received final audit recommendation for ISO 2 Customer Service & Support. 27001. “Unparalleled customer suppo
Slide 20: Product and Software Updates
Product and Software Updates ● Radiology Information System ● Universal Viewer v6.3.2 Enhancements (cont.) ➢ Wide range of new features and ➢ New authentication service, standard for log functionalities developed for the enhanced storage, improvement on loading speed of iteration of AQUILA (the RIS-
Slide 21: Focus for FY25
Focus for FY25 Software Radiology Services ● Roll out the New Value Proposition ➢ Enhanced digital security: Achieve ISO ● Focus on profitability: successfully renegotiated 27001 certification key contracts with better pricing, improving ➢ Service excellence: Delivering the best margins in early 202
Slide 22: Business Update
Business Update • Advanced negotiations for a material radiology • The Company has recently completed the first contract of a public hospital district in Bogota, commercial stage and has commenced selling and Colombia: installing major new software development Aquila+: ➢ The hospital district has th
Slide 23: FY25 Outlook
FY25 Outlook H1 FY25 • Continuing momentum from go live of recent Key drivers for revenue and earnings contracts. • Upfront launch costs for marketing and sales for growth: New Value Proposition (Aquila+). • Annualised Recurring H2 FY25 Revenue together with current • Radiology Profit Improvement Pr
Slide 24: Capital Raising
ime<HS Capital Raising
Slide 25: Details of the Offer
Details of the Offer Offer Structure and • A Placement (“Placement”) of fully paid ordinary shares (New Shares) to raise $2.5m, consisting of Size two parts: • Tranche 1 – an institutional placement to raise $1.5m (“Institutional Placement”); and • Tranche 2 – a placement of $1.0m to Directors subje
Slide 26: Indicative Timetable
Indicative Timetable INDICATIVE PLACEMENT TIMETABLE Event 2025 Record date for SPP 7.00pm (AEDT) on Tuesday, 1 April 2025 Trading halt (pre-market open) Wednesday, 2 April 2025 Trading halt lifted – Shares recommence trading on ASX Thursday, 3 April 2025 Settlement of Institutional Placement Friday,
Slide 27: Use of Proceeds & Capital Structure
Use of Proceeds & Capital Structure Sources $m Capital Structure $m Placement 2.5 Current Market Capitalisation at 1 April 2025 18.1 Share Purchase Plan 1.0 Equity Raising2 2.5 Total 3.5 Uses1 $m Cash3 (2.1) Working Capital and drive Aquila+ sales 3.5 Debt3 1.2 Total 3.5 Total Enterprise Valuation 1
Slide 28: Key Risks
Key Risks This section sets out some of the key risks associated with any investment in IMEXHS, which may affect the value of IMEXHS Shares. The risks set out below are not necessarily listed in order of importance and do not constitute an exhaustive list of all risks involved with an investment in
Slide 29: Key Risks
Key Risks Risk Description The Company advises it is in advanced negotiations for a material radiology contract of a public hospital district in Bogota, Colombia. The hospital district has three major hospitals and 19 outpatient clinics and currently uses IMEXHS software throughout its hospitals. Th
Slide 30: Key Risks
Key Risks Risk Description The funds to be raised under the Placement and Entitlement Offer are considered sufficient to meet the current objectives of IMEXHS. However, additional funding may be required to fund future growth strategies. The Conditional Placement is subject to the approval of IMEXHS
Slide 31: Key Risks
Key Risks Risk Description IMEXHS uses off-the-shelf software (in addition to its own proprietary software) to enable the functionality of its product offerings. This external software may be subject to issues outside of IMEXHS’s control such as third party interfaces, version External technology co
Slide 32: Key Risks
Key Risks Risk Description IMEXHS will need to continue to expand its operations if it successfully achieves market acceptance of its products and Ability to manage services in new markets. IMEXHS’s existing systems, procedures and resources may not be adequate to support such growth effectively exp
Slide 33: Key Risks
Key Risks Risk Description IMEXHS currently has employees in Colombia and Mexico and distributors engaged in Mexico and other Latin American countries. IMEXHS may wish to engage further employees and distributors outside of Australia as it grows its existing business Doing business and expands to ne
Slide 34: Q&A
Q&A
Slide 35: Disclaimer
Disclaimer Disclaimer This presentation has been prepared by, and is the sole responsibility of, IMEXHS Limited ACN 096 687 839 (the Company) and is dated 3 April 2025. The Company is under no obligation to update or keep the information represented in this presentation current past the date of pres
Slide 36: Disclaimer
Disclaimer Forward-looking statements (cont.) The Company, the Lead Manager and any of their respective related bodies corporate and affiliates, and their respective officers, directors, employees, agents, partners, contractors or advisers (collectively, Associated Persons) disclaim any obligation o
Slide 37: Disclaimer
Disclaimer Past Performance Past performance detailed in this presentation is given for illustrative purposes only and should not be relied upon as an indication of the Company’s views on its future financial performance or condition. Readers should note that past performance of the Company cannot b
Slide 38: FY24 Results and capital raising
FY24 Results and capital raising 3 April 2025